MX2008012748A - Un proceso para la concentracion de un polipeptido. - Google Patents

Un proceso para la concentracion de un polipeptido.

Info

Publication number
MX2008012748A
MX2008012748A MX2008012748A MX2008012748A MX2008012748A MX 2008012748 A MX2008012748 A MX 2008012748A MX 2008012748 A MX2008012748 A MX 2008012748A MX 2008012748 A MX2008012748 A MX 2008012748A MX 2008012748 A MX2008012748 A MX 2008012748A
Authority
MX
Mexico
Prior art keywords
polypeptide
concentration
composition
mammals
concentrating
Prior art date
Application number
MX2008012748A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Nilsson
Original Assignee
Shire Pharmaceuticals Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Ireland filed Critical Shire Pharmaceuticals Ireland
Publication of MX2008012748A publication Critical patent/MX2008012748A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2008012748A 2006-04-04 2007-04-04 Un proceso para la concentracion de un polipeptido. MX2008012748A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (1)

Publication Number Publication Date
MX2008012748A true MX2008012748A (es) 2009-01-07

Family

ID=38472949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012748A MX2008012748A (es) 2006-04-04 2007-04-04 Un proceso para la concentracion de un polipeptido.

Country Status (20)

Country Link
US (6) US20090246187A1 (https=)
EP (4) EP2628746B1 (https=)
JP (6) JP2009532394A (https=)
KR (3) KR101504969B1 (https=)
CN (1) CN105233276A (https=)
AU (2) AU2007234195B2 (https=)
BR (1) BRPI0709737A2 (https=)
CA (3) CA2644642C (https=)
DK (1) DK2628746T3 (https=)
ES (3) ES2928096T3 (https=)
HU (1) HUE042402T2 (https=)
IL (4) IL194267A (https=)
MX (1) MX2008012748A (https=)
NO (3) NO347673B1 (https=)
NZ (7) NZ607595A (https=)
PL (3) PL2631242T3 (https=)
PT (1) PT2628746T (https=)
SI (1) SI2628746T1 (https=)
WO (1) WO2007112757A2 (https=)
ZA (2) ZA200805346B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713904B1 (en) 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
HRP20191923T1 (hr) * 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
NZ707753A (en) * 2012-11-13 2019-07-26 Chiesi Farm Spa Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
CA2893609A1 (en) * 2012-12-11 2014-06-19 Centogene Ag Method for the diagnosis of metachromatic leukodystrophy
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) * 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation PROCESS FOR PURIFYING A SULFATASE PROTEIN
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) * 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
DE69901536T2 (de) 1998-01-27 2003-01-16 Hemebiotech A/S, Hellerod Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
IL140155A (en) * 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP2003505057A (ja) 1999-07-27 2003-02-12 ヘム−バイオテック エイ／エス ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
WO2002099092A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
EP1713904B1 (en) * 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
WO2005094874A1 (en) 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére

Also Published As

Publication number Publication date
US20090246187A1 (en) 2009-10-01
US20180289777A1 (en) 2018-10-11
AU2008229659B2 (en) 2013-01-31
JP2014051503A (ja) 2014-03-20
BRPI0709737A2 (pt) 2011-07-26
IL194267A0 (en) 2011-08-01
ZA200809540B (en) 2019-09-25
ES2744499T3 (es) 2020-02-25
NO20082510L (no) 2008-10-31
KR101504969B1 (ko) 2015-03-24
JP5878152B2 (ja) 2016-03-08
JP2009532394A (ja) 2009-09-10
EP2631242B1 (en) 2022-08-03
KR20150103339A (ko) 2015-09-09
CA2644642C (en) 2016-01-26
JP2014058521A (ja) 2014-04-03
HUE042402T2 (hu) 2019-06-28
AU2008229659A1 (en) 2008-10-23
IL241654A0 (en) 2015-11-30
JP2013236633A (ja) 2013-11-28
US20120076767A1 (en) 2012-03-29
JP5384232B2 (ja) 2014-01-08
EP2004672A2 (en) 2008-12-24
IL241654B (en) 2019-02-28
EP2100898A1 (en) 2009-09-16
IL235982A0 (en) 2015-01-29
AU2007234195A1 (en) 2007-10-11
CA2632528C (en) 2022-07-12
EP2100898B1 (en) 2019-06-19
NO20211305A1 (no) 2008-10-31
NZ607595A (en) 2014-10-31
US9713634B2 (en) 2017-07-25
PL2100898T3 (pl) 2019-11-29
EP2631242A2 (en) 2013-08-28
SI2628746T1 (sl) 2019-04-30
NO20084776L (no) 2008-10-31
NZ597548A (en) 2013-08-30
JP2009273469A (ja) 2009-11-26
IL194267A (en) 2015-10-29
DK2628746T3 (en) 2019-04-01
US20170202927A1 (en) 2017-07-20
EP2004672B1 (en) 2015-08-19
CN105233276A (zh) 2016-01-13
EP2628746B1 (en) 2019-01-09
NZ623123A (en) 2015-04-24
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
NZ582045A (en) 2011-07-29
PT2628746T (pt) 2019-04-23
KR20090018894A (ko) 2009-02-24
EP2631242A3 (en) 2013-10-02
US8809055B2 (en) 2014-08-19
NZ568728A (en) 2011-09-30
IL211905A0 (en) 2011-05-31
CA2632528A1 (en) 2007-10-11
US20140314735A1 (en) 2014-10-23
NO346368B1 (no) 2022-06-27
JP2016104000A (ja) 2016-06-09
US20160193304A1 (en) 2016-07-07
NZ588903A (en) 2012-08-31
ES2713488T3 (es) 2019-05-22
AU2007234195B2 (en) 2013-02-07
PL2631242T3 (pl) 2023-03-20
ZA200805346B (en) 2018-11-28
PL2628746T3 (pl) 2019-07-31
CA2882501A1 (en) 2007-10-11
EP2628746A2 (en) 2013-08-21
NO347673B1 (no) 2024-02-19
EP2628746A3 (en) 2014-03-19
WO2007112757A2 (en) 2007-10-11
CA2882501C (en) 2021-09-07
ES2928096T3 (es) 2022-11-15
CA2644642A1 (en) 2007-10-11
KR20140057678A (ko) 2014-05-13

Similar Documents

Publication Publication Date Title
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
PH12015502433A1 (en) Fgf21 mutants and uses thereof
EA201690946A1 (ru) Мутанты fgf21 и их применение
UA101155C2 (ru) Модифицированный полипептид фактора vii (fvii) и его применение
WO2006104913A3 (en) USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
TN2011000161A1 (en) Fgf21 mutants and uses thereof
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
NZ601142A (en) Composition for improving brain function and method for improving brain function
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
MX2010010177A (es) Fragmentos de beta timosina mejorada.
EA201290457A1 (ru) СЛИТЫЙ БЕЛОК BChE-АЛЬБУМИН ДЛЯ ЛЕЧЕНИЯ ЗЛОУПОТРЕБЛЕНИЯ КОКАИНОМ
TW200716132A (en) Novel chemical compounds
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
WO2005009361A3 (en) Method of treating hit patients with argatroban
GB2450660A (en) Peptide derived from colostrum
GB0818080D0 (en) Immunogenic peptides

Legal Events

Date Code Title Description
FG Grant or registration